Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.

Cancer letters - 10 Sept 2017

Liang Zhiyong, Cheng Ying, Chen Yuan, Hu Yanping, Liu Wei-Ping, Lu You, Wang Jie, Wang Ye, Wu Gang, Ying Jian-Ming, Zhang He-Long, Zhang Xu-Chao, Wu Yi-Long

Abstract excerpt

Somatic mutation in the epidermal growth factor receptor (EGFR) predict clinical response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) and is a promising target for personalised medicine. EGFR mutations have prognostic value. Initially patients respond well to tyrosine kinase inhibitors but finally they would develop resistance and about 50% of this resistance can be attributed to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplastic Cells, Circulating

Share to Patient Selection

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 28642172
DOI: 10.1016/j.canlet.2017.06.008

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.PMID 28642172Read ↗

Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancerSemantic proximity Read ↗

Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.Semantic proximity Read ↗

The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.Semantic proximity Read ↗

Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancerSemantic proximity Read ↗

OA 09.01 Characterizing the Genomic Landscape of EGFR C797S in Lung Cancer Using ctDNA Next-Generation SequencingSemantic proximity Read ↗

Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC.Semantic proximity Read ↗

Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patientsSemantic proximity Read ↗

Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.Semantic proximity Read ↗

A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancerSemantic proximity Read ↗

Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.Semantic proximity Read ↗

Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.